» Articles » PMID: 21310283

Effects of an Estrogen-free, Desogestrel-containing Oral Contraceptive in Women with Migraine with Aura: a Prospective Diary-based Pilot Study

Overview
Journal Contraception
Publisher Elsevier
Date 2011 Feb 12
PMID 21310283
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Migraine with aura (MA) is a contraindication to the use of combined oral contraceptives (COCs) because of the increased risk of ischemic stroke. Progestogen-only contraceptive pill (POP) is a safe alternative to COCs and it is preferable in women with cerebrovascular diseases or risk factors for stroke.

Study Design: Prospective diary-based pilot study. Thirty women with MA (n = 15 who have never used COCs and n = 15 who had previously used COCs were diagnosed according to the International Headache Society criteria. The observational period lasted 9 months during which women filled in a diary with the clinical characteristics of headache attacks. After a 3-month run-in period, each subject received an estrogen-free desogestrel (DSG) (75 mcg/day)-containing OC (Cerazette(®); Schering-Plough, formerly NV Organon, Oss, The Netherlands). Follow-up evaluations were planned at the end of the third and sixth month of treatment.

Results: The number (mean±S.D.) of migraine attacks was significantly reduced both in previous COCs users (from 3.9±1.0 to 2.9±0.8; p<.001) and nonusers (from 3.2±0.9 to 2.6±1.3; p<.02) following 6 months of POP use in comparison with the run-in period. Duration of headache pain did not differ significantly in both groups throughout the study. Interestingly enough, a beneficial POP effect on the duration (mean±S.D.) of visual aura (from 16.3±9.5 to 11.4±5.6 min) and on the total duration (mean±S.D.) of neurological symptoms (from 33.6±23.3 to 18.6±18.0 min) was only significantly reported by previous COCs users (p<.001, for both) by the end of the study period. The POP was well tolerated by each woman and the bleeding pattern was variable with a tendency towards infrequent bleeding.

Conclusions: The present study supports the use of the POP containing desogestrel in a population of women with MA and underlines a positive effect on symptoms of aura, especially in MA sensitive to previous use of COCs.

Citing Articles

Investigating migraine phenotype and dynamics in women with endometriosis: an observational pilot study.

Merki-Feld G, Dietrich H, Imesch P, Gantenbein A, Sandor P, Schankin C Acta Neurol Belg. 2024; 124(4):1263-1271.

PMID: 38878131 PMC: 11266208. DOI: 10.1007/s13760-024-02484-2.


Progesterone Receptor Activation Regulates Sensory Sensitivity and Migraine Susceptibility.

Joshi S, Williamson J, Moosa S, Kapur J J Pain. 2023; 25(3):642-658.

PMID: 37777034 PMC: 11758909. DOI: 10.1016/j.jpain.2023.09.017.


Migraine and Hormonal Contraception in Gynecological Outpatient Care-Cross-Sectional Study among Practicing Gynecologists in Germany.

Fitzek M, Storch E, Overeem L, Kull P, Terhart M, Lange K J Clin Med. 2023; 12(4).

PMID: 36835967 PMC: 9958685. DOI: 10.3390/jcm12041434.


Role of Estrogens in Menstrual Migraine.

Nappi R, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C Cells. 2022; 11(8).

PMID: 35456034 PMC: 9025552. DOI: 10.3390/cells11081355.


Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study.

Merki-Feld G, Sandor P, Nappi R, Pohl H, Schankin C Acta Neurol Belg. 2021; 122(2):401-409.

PMID: 33928470 PMC: 8986701. DOI: 10.1007/s13760-021-01677-3.